Three-year outcome of rivastigmine treatment in Alzheimer's disease in a routine clinical setting.
Objectives: Long-term, placebo-controlled studies of cholinesterase inhibitors (ChEIs) in Alzheimer’s disease (AD) are not permitted for ethical reasons. Therefore, the advancement of knowledge on longitudinal outcomes in different domains warrants well-designed naturalistic studies. The aim of this study was to explore the 3-year effectiveness of rivastigmine treatment. Methods: The Swedish Alzhe
